Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1991 1
1995 1
1998 1
1999 2
2000 2
2001 5
2002 1
2003 3
2009 1
2012 1
2013 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
The following terms were not found in PubMed: Ticalopride, Ticalopride
Page 1
Did you mean Norcisapride OR eticlopride OR eticlopride (703 results)?
Red wine-cisapride interaction: comparison with grapefruit juice.
Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG. Offman EM, et al. Clin Pharmacol Ther. 2001 Jul;70(1):17-23. doi: 10.1067/mcp.2001.116892. Clin Pharmacol Ther. 2001. PMID: 11452240 Clinical Trial.
The time to reach maximum concentration after drug administration (t(max)) and the apparent elimination half-life (t((1/2)) for cisapride and the pharmacokinetics of norcisapride were not altered. Norcisapride/cisapride ratios were reduced. ...The cisapride t(max) w …
The time to reach maximum concentration after drug administration (t(max)) and the apparent elimination half-life (t((1/2)) for cisapride an …
Influence of grapefruit juice on cisapride pharmacokinetics.
Gross AS, Goh YD, Addison RS, Shenfield GM. Gross AS, et al. Clin Pharmacol Ther. 1999 Apr;65(4):395-401. doi: 10.1016/S0009-9236(99)70133-5. Clin Pharmacol Ther. 1999. PMID: 10223776 Clinical Trial.
Blood samples were taken for 25 hours and urine was collected for 36 hours after dosing. Plasma concentrations of cisapride and urinary norcisapride were measured by HPLC. The influence of grapefruit juice on pharmacokinetic parameters (mean +/- SD) was assessed with the W …
Blood samples were taken for 25 hours and urine was collected for 36 hours after dosing. Plasma concentrations of cisapride and urinary n …
Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
Pearce RE, Gotschall RR, Kearns GL, Leeder JS. Pearce RE, et al. Drug Metab Dispos. 2001 Dec;29(12):1548-54. Drug Metab Dispos. 2001. PMID: 11717173
Identification of the human cytochrome P450 (P450) enzymes involved in the metabolism of cisapride and racemic norcisapride [(+/-)-norcisapride] was investigated at 0.1 and 1 microM, concentrations that span the mean plasma C(max) for cisapride. Formation of norc …
Identification of the human cytochrome P450 (P450) enzymes involved in the metabolism of cisapride and racemic norcisapride [(+/-)- …
Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.
Kearns GL, Robinson PK, Wilson JT, Wilson-Costello D, Knight GR, Ward RM, van den Anker JN; Pediatric Pharmacology Research Unit Network. Kearns GL, et al. Clin Pharmacol Ther. 2003 Oct;74(4):312-25. doi: 10.1016/S0009-9236(03)00225-X. Clin Pharmacol Ther. 2003. PMID: 14534518 Clinical Trial.
METHODS: A total of 35 infants with a postconceptional age of 28 to 54 weeks at the time of the study received a single oral cisapride dose (0.2 mg/kg) at a postnatal age of 4 to 102 days, followed by repeated (n = 7) blood sampling over a 24-hour period. Cisapride and norcisa …
METHODS: A total of 35 infants with a postconceptional age of 28 to 54 weeks at the time of the study received a single oral cisapride dose …
Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction.
Lee-Montiel FT, Laemmle A, Charwat V, Dumont L, Lee CS, Huebsch N, Okochi H, Hancock MJ, Siemons B, Boggess SC, Goswami I, Miller EW, Willenbring H, Healy KE. Lee-Montiel FT, et al. Front Pharmacol. 2021 May 7;12:667010. doi: 10.3389/fphar.2021.667010. eCollection 2021. Front Pharmacol. 2021. PMID: 34025426 Free PMC article.
As seen in patients, metabolic conversion of cisapride to non-arrhythmogenic norcisapride in the liver MPS by the cytochrome P450 enzyme CYP3A4 was inhibited by ketoconazole, leading to arrhythmia in the cardiac MPS. ...
As seen in patients, metabolic conversion of cisapride to non-arrhythmogenic norcisapride in the liver MPS by the cytochrome P450 enz …
The effect of cisapride on the corrected QT interval and QT dispersion in premature infants.
Cools F, Benatar A, Bougatef A, Vandenplas Y. Cools F, et al. J Pediatr Gastroenterol Nutr. 2001 Aug;33(2):178-81. doi: 10.1097/00005176-200108000-00015. J Pediatr Gastroenterol Nutr. 2001. PMID: 11568520
Trough and anticipated peak plasma level of cisapride and norcisapride were quantified after 72 hours of treatment. Results were compared with a cohort of 41 term infants aged 0 to 3 months receiving cisapride treatment. ...The change in QTc interval was inversely related …
Trough and anticipated peak plasma level of cisapride and norcisapride were quantified after 72 hours of treatment. Results were comp …
A simple high-performance liquid chromatography assay for the major cisapride metabolite, norcisapride, in human urine.
Addison RS, Duffy SL, Mathers SR. Addison RS, et al. J Chromatogr Sci. 1999 Mar;37(3):61-4. doi: 10.1093/chromsci/37.3.61. J Chromatogr Sci. 1999. PMID: 10089595
A simple high-performance liquid chromatography assay using fluorescence detection for the major metabolite of the gastric prokinetic drug cisapride, norcisapride, is presented. Analysis is performed using an Alltech Platinum EPS C8 column with a mobile phase made up of me …
A simple high-performance liquid chromatography assay using fluorescence detection for the major metabolite of the gastric prokinetic drug c …
Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, Kashuba AD, Schuetz EG, Bertino JS Jr, van den Anker JN, Leeder JS. Lowry JA, et al. Clin Pharmacol Ther. 2003 Mar;73(3):209-22. doi: 10.1067/mcp.2003.29. Clin Pharmacol Ther. 2003. PMID: 12621386 Clinical Trial.
Plasma concentrations were quantitated from repeated after-dosing blood samples by HPLC with ultraviolet detection for midazolam and HPLC with tandem mass spectrometry detection for cisapride and norcisapride. Pharmacokinetic parameters were determined by noncompartmental …
Plasma concentrations were quantitated from repeated after-dosing blood samples by HPLC with ultraviolet detection for midazolam and HPLC wi …
Excretion and biotransformation of cisapride in dogs and humans after oral administration.
Meuldermans W, Van Peer A, Hendrickx J, Lauwers W, Swysen E, Bockx M, Woestenborghs R, Heykants J. Meuldermans W, et al. Drug Metab Dispos. 1988 May-Jun;16(3):403-9. Drug Metab Dispos. 1988. PMID: 2900732
N-Deal-kylation at the piperidine nitrogen resulting in the main urinary metabolite, norcisapride, and aromatic hydroxylation of the 4-fluorophenyl ring were major metabolic pathways in both species. Norcisapride excretion accounted for 14% of the dose in dogs and 4 …
N-Deal-kylation at the piperidine nitrogen resulting in the main urinary metabolite, norcisapride, and aromatic hydroxylation of the …
Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae.
Chai W, Chan KY, de Vries R, van den Bogeardt AJ, de Maeyer JH, Schuurkes JA, Villalón CM, Saxena PR, Danser AH, MaassenVanDenBrink A. Chai W, et al. Life Sci. 2012 Apr 9;90(13-14):538-44. doi: 10.1016/j.lfs.2012.01.009. Epub 2012 Feb 1. Life Sci. 2012. PMID: 22326501
We pharmacologically evaluated the gastroprokinetic 5-HT(4) receptor agonists tegaserod, prucalopride, R199715, cisapride, the cisapride metabolite norcisapride, and the 5-HT(3) receptor agonist MKC773 on human isolated myocardial trabeculae, and compared their effects wit …
We pharmacologically evaluated the gastroprokinetic 5-HT(4) receptor agonists tegaserod, prucalopride, R199715, cisapride, the cisapride met …
22 results